Zoledronic Acid 4 mg / 5 ml. Concentrated solution for intravenous infusion.
Osteoclastic resortion inhibitor.
ALAMUR® 4 mg / 5 ml. Concentrate solution, package containing 1 vial.
Hypercalcemia of Malignancy. Multiple Myeloma and documented Bone Metastases of solid tumors in conjunction with standard antineoplastic therapy. Prostate Cancer should have progressed after treatment with at least one hormonal therapy.
Dose and administration:
The recommended dose of ALAMUR® in patients with Multiple Myeloma and Metastatic Bone lesions from solid tumors for patients with creatinine clearance greater than 60 ml/min is 4 mg infused over no less than 15 minutes every 3 - 4 weeks. The optimal duration of therapy is not known. For Hypercalcemia of Malignancy and extended information about all indications, read the full prospect.
Store between 15ºC and 25°C.